COR
NYSE Cencora, Inc.$309.05 ↑ +0.00 (+0.00%) Trading Up from the previous close of $309.05, $1.38 below the day’s high of $310.43
- YTD change
- -8.50%
- vs 20-day SMA
- -2.30%
- vs 200-day SMA
- -2.93%
Price ranges
Price & Performance
-11.91 (-3.71%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 18.1% away from all-time highs of $377.54
- COR is down 8% since the beginning of the year
- COR is up 0% over the past 12 months
- COR is down 8% over the past 1 month
- 2% of all COR investors are betting against COR
- Number of investors short COR has gone down 5% versus last month
COR reads neutral: price sits below both the 20- and 200-day averages, short interest is falling month over month, the 12-month move is +2.1%.
- Previous minute
- +$0.00
- Last hour
- +$0.04
- Last 5 days
- -0.26%
- vs 8-day SMA
- +0.30%
No alerts for COR in the last day.
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. The U.S. Healthcare Solutions segment is involved in the offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers. The International Healthcare Solutions segment includes businesses that focus on international pharmaceutical wholesale and related service operations, and global commercialization services. The company was founded by Emil P. Martini in 1947 and is headquartered in Conshohocken, PA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.